Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017)
Quarterly results put Income from Non-Controlling Interests at -$1.1 million for Q1 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was -$1.1 million (changed N/A YoY), and the annual figure for FY2017 was -$1.1 million, up 52.55%.
Solid Biosciences has reported Income from Non-Controlling Interests over the past 1 years, most recently at -$1.1 million for Q1 2017.
- Income from Non-Controlling Interests reached -$1.1 million in Q1 2017 per SLDB's latest filing.
- Across five years, Income from Non-Controlling Interests topped out at -$1.1 million in Q1 2017 and bottomed at -$1.1 million in Q1 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -1.06 Mn |